Skip to main content
. 2021 Jan;10(1):279–291. doi: 10.21037/tlcr-20-709

Table 2. Demographic information for patients with stage IV NSCLC after PSM.

Surgery to primary site (n=2,436), n (%) Non-surgery to primary site (n=2,436), n (%) P
Age 0.877
   Mean 63.97 63.56
   SD 10.88 11.02
Gender 0.566
   Male 1,261 (51.77) 1,247 (51.19)
   Female 1,175 (48.23) 1,189 (48.81)
Race 0.994
   White 1,995 (81.90) 1,994 (81.80)
   Black 268 (11.00) 273 (11.20)
   Other 173 (7.10) 169 (7.00)
T stage 0.673
   T1 1,006 (41.30) 946 (38.80)
   T2 610 (25.04) 624 (25.60)
   T3 380 (15.60) 415 (17.00)
   T4 440 (18.06) 451 (18.60)
N stage 0.142
   N0 1,168 (47.95) 1,158 (47.60)
   N1 383 (15.72) 345 (14.20)
   N2 765 (31.40) 785 (32.20)
   N3 120 (4.93) 148 (6.00)
M stage 0.758
   M1a 774 (31.77) 771 (31.6)
   M1b 1,662 (68.23) 1,665 (68.4)
Tumor position 0.929
   Right bronchus 44 (1.81) 43 (1.77)
   Right upper lobe 452 (18.56) 460 (18.88)
   Right middle lobe 749 (30.75) 744 (30.54)
   Right lower lobe 133 (5.46) 129 (5.30)
   Left bronchus 24 (0.99) 26 (1.10)
   Left upper lobe 650 (26.68) 642 (26.35)
   Left lower lobe 321 (13.18) 330 (13.55)
   Over lapping lesion 63 (2.59) 56 (2.20)
Histology 0.878
   Large cell 115 (4.72) 105 (4.40)
   Adenocarcinoma 1,649 (67.69) 1,663 (68.20)
   Squamous cell 560 (22.99) 567 (23.20)
   Adeno-squamous 80 (3.28) 66 (2.80)
   Neuroendocrine 32 (1.31) 35 (1.40)
Grade 0.492
   I 195 (8.00) 173 (7.20)
   II 904 (37.11) 885 (36.40)
   III 1,240 (50.90) 1,281 (52.60)
   IV 97 (3.98) 97 (4.00)
Radiation 0.686
   Yes 1,087 (44.62) 1,346 (55.20)
   None/unknown 1,349 (55.38) 1,090 (44.80)
Chemotherapy 0.437
   Yes 1,354 (55.58) 1,080 (44.40)
   None/unknown 1,082 (44.42) 1,356 (56.60)
Surgery to other sites 0.469
   Yes 374 (15.35) 355 (14.60)
   None/unknown 2,062 (84.65) 2,436 (85.40)

NSCLC, non-small cell lung cancer; PSM, propensity score matching; SD, Standard deviation.